Renaissance Capital logo

Atara Biotherapeutics Priced, Nasdaq: ATRA

Early-stage biotech targeting muscle loss in patients with end-stage renal disease.

Industry: Health Care

First Day Return: -3.2%

Early-stage biotech targeting muscle loss in patients with end-stage renal disease.

Atara Biotherapeutics (ATRA) Performance

Created with Highcharts 10.3.2Chart context menuATRA vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index